What it sells
Patient-derived AI drug discovery platform.
Business model breakdown
Trigger: what makes them buy now?
Company says 57% of clinical failures come from inadequate efficacy, motivating training on end-stage patient tissue.
Workflow: what inputs become what output?
Treatment-resistant patient tissue is grown into organoids, robotic imaging generates drug-response data, deep learning designs molecules, which are synthesized and tested with results fed back (400+ molecules per program).
Economics: what it saves and how it charges
Builds a pipeline of proprietary small-molecule assets across multiple disease areas (biotech asset model).
Distribution: how it reaches customers
UnverifiedBuilds a proprietary small-molecule pipeline across three modalities; no partnering terms published.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07-17 | — | €3M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.